Recombinant Human CILP-1 Protein, CF Summary
Product Specifications
The ED50 for this effect is 0.5-2.0 μg/mL.
Optimal dilutions should be determined by each laboratory for each application. Also measured by its ability to bind Recombinant Human TGF‑ beta 1 (Catalog # 240-B).
Met1-Arg720, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
5504-CP
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution | Reconstitute at 100 μg/mL in PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: CILP-1
CILP‑1 (cartilage intermediate‑layer protein 1; CILP C1) is a 92 kDa secreted monomeric cartilage glycoprotein that is the N‑terminal portion of a proteolytically cleaved 138 kD precursor (1, 2). The 62 kDa C‑terminal fragment, called CILP C2, is also secreted; while thought to resemble a nucleoside triphosphate pyrophosphohydrolase (NTPPHase), it has no enzyme activity (2 ‑ 4). Mature human CILP‑1 (aa 22 ‑ 720) contains a TSP‑1 domain (aa 149 ‑ 201) and a C2‑type Ig‑like region (aa 309 ‑ 395) and shares 89% and 42% aa sequence identity with mouse CILP‑1 and human CILP‑2, respectively. CILP‑1 is produced by chondrocytes in both hyaline and fibrocartilage, and preferentially found in the inter‑territorial matrix of the interior layers of articular cartilage (1, 2). Its expression increases with age and correlates with osteoarthritis (1, 2, 5 ‑ 7). While CILP‑1 expression is induced by TGF‑ beta 1‑activated SMAD3, the secreted protein binds and inhibits TGF‑ beta 1 activities, such as induction of cartilage matrix genes (4 ‑ 6, 8). A polymorphism producing the aa substitution I395T enhances inhibition of TGF‑ beta 1 and is significantly associated with lumbar disc disease in Japanese populations, but not in Finnish or Chinese populations (4, 9). Additionally, chondrocyte CILP‑1 expression is inhibited by IGF‑1 in vitro, but CILP‑1 protein blocks IGF‑1 activities such as proliferation and down‑regulation of extracellular inorganic pyrophosphate (ePPi) production (3, 5, 6). In a model of aged cartilage where TGF‑ beta 1 is dominant, increased CILP‑1 inhibits both IGF‑1 and TGF‑ beta 1 activities, slowing cartilage repair due to reduced chondrocyte proliferation and matrix production. At the same time, increased production of ePPi promotes crystals that are a factor in osteoarthritis (3).
- Lorenzo, P. et al. (1998) J. Biol. Chem. 273:23469.
- Lorenzo, P. et al. (1998) J. Biol. Chem. 273:23463.
- Johnson, K. et al. (2003) Arthritis Rheum. 48:1302.
- Seki, S. et al. (2005) Nat. Genet. 37:607.
- Hirose, J. et al. (2002) Arthritis Rheum. 46:3218.
- Hirose, J. et al. (2000) Arthritis Rheum. 43:2703.
- Lorenzo, P. et al. (2004) Matrix Biol. 23:381.
- Mori, M. et al. (2006) Biochem. Biophys. Res. Commun. 341:121.
- Virtanen, I.M. et al. (2007) J. Med. Genet. 44:285.
Citation for Recombinant Human CILP-1 Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling
Authors: FA van Nieuwe, C Munts, RC Op't Veld, A González, J Díez, S Heymans, B Schroen, M van Bilsen
Sci Rep, 2017-11-22;7(1):16042.
Species: Human, Rat
Sample Types: Whole Cells
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human CILP-1 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human CILP-1 Protein, CF and earn rewards!
Have you used Recombinant Human CILP-1 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image